194 related articles for article (PubMed ID: 23977339)
21. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.
Burton DR; Hessell AJ; Keele BF; Klasse PJ; Ketas TA; Moldt B; Dunlop DC; Poignard P; Doyle LA; Cavacini L; Veazey RS; Moore JP
Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11181-6. PubMed ID: 21690411
[TBL] [Abstract][Full Text] [Related]
22. Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge.
Julg B; Tartaglia LJ; Keele BF; Wagh K; Pegu A; Sok D; Abbink P; Schmidt SD; Wang K; Chen X; Joyce MG; Georgiev IS; Choe M; Kwong PD; Doria-Rose NA; Le K; Louder MK; Bailer RT; Moore PL; Korber B; Seaman MS; Abdool Karim SS; Morris L; Koup RA; Mascola JR; Burton DR; Barouch DH
Sci Transl Med; 2017 Sep; 9(406):. PubMed ID: 28878010
[TBL] [Abstract][Full Text] [Related]
23. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
[TBL] [Abstract][Full Text] [Related]
24. Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying
Scinto HB; Gupta S; Thorat S; Mukhtar MM; Griffiths A; Delgado J; Plake E; Vyas HK; Strickland A; Byrareddy SN; Montefiori DC; LaBranche C; Pal R; Treece J; Orndorff S; Ferrari MG; Weiss D; Chenine AL; McLinden R; Michael N; Kim JH; Robb ML; Rerks-Ngarm S; Pitisuttithum P; Nitayaphan S; Ruprecht RM
J Virol; 2018 Jul; 92(14):. PubMed ID: 29743361
[TBL] [Abstract][Full Text] [Related]
25. Development of Antibodies with Broad Neutralization Specificities against HIV-1 after Long Term SHIV Infection in Macaques.
Gao N; Gai Y; Meng L; Wang C; Zhang X; Wang W; Qin C; Yu X; Gao F
Viruses; 2020 Jan; 12(2):. PubMed ID: 32023860
[TBL] [Abstract][Full Text] [Related]
26. Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.
Mascola JR; Lewis MG; VanCott TC; Stiegler G; Katinger H; Seaman M; Beaudry K; Barouch DH; Korioth-Schmitz B; Krivulka G; Sambor A; Welcher B; Douek DC; Montefiori DC; Shiver JW; Poignard P; Burton DR; Letvin NL
J Virol; 2003 Oct; 77(19):10348-56. PubMed ID: 12970419
[TBL] [Abstract][Full Text] [Related]
27. Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.
Mörner A; Jansson M; Bunnik EM; Schøller J; Vaughan R; Wang Y; Montefiori DC; Otting N; Bontrop R; Bergmeier LA; Singh M; Wyatt RT; Schuitemaker H; Biberfeld G; Thorstensson R; Lehner T
J Virol; 2011 Jul; 85(13):6442-52. PubMed ID: 21490092
[TBL] [Abstract][Full Text] [Related]
28. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges.
Gautam R; Nishimura Y; Pegu A; Nason MC; Klein F; Gazumyan A; Golijanin J; Buckler-White A; Sadjadpour R; Wang K; Mankoff Z; Schmidt SD; Lifson JD; Mascola JR; Nussenzweig MC; Martin MA
Nature; 2016 May; 533(7601):105-109. PubMed ID: 27120156
[TBL] [Abstract][Full Text] [Related]
29. A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV.
Moldt B; Schultz N; Dunlop DC; Alpert MD; Harvey JD; Evans DT; Poignard P; Hessell AJ; Burton DR
J Virol; 2011 Oct; 85(20):10572-81. PubMed ID: 21849450
[TBL] [Abstract][Full Text] [Related]
30. Pathogenic infection of Macaca nemestrina with a CCR5-tropic subtype-C simian-human immunodeficiency virus.
Ho O; Larsen K; Polacino P; Li Y; Anderson D; Song R; Ruprecht RM; Hu SL
Retrovirology; 2009 Jul; 6():65. PubMed ID: 19602283
[TBL] [Abstract][Full Text] [Related]
31. Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.
Bolton DL; Pegu A; Wang K; McGinnis K; Nason M; Foulds K; Letukas V; Schmidt SD; Chen X; Todd JP; Lifson JD; Rao S; Michael NL; Robb ML; Mascola JR; Koup RA
J Virol; 2016 Feb; 90(3):1321-32. PubMed ID: 26581981
[TBL] [Abstract][Full Text] [Related]
32. Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus.
Kumar A; Mukherjee S; Shen J; Buch S; Li Z; Adany I; Liu Z; Zhuge W; Piatak M; Lifson J; McClure H; Narayan O
Virology; 2002 Sep; 301(2):189-205. PubMed ID: 12359422
[TBL] [Abstract][Full Text] [Related]
33. Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques.
Foresman L; Jia F; Li Z; Wang C; Stephens EB; Sahni M; Narayan O; Joag SV
AIDS Res Hum Retroviruses; 1998 Aug; 14(12):1035-43. PubMed ID: 9718118
[TBL] [Abstract][Full Text] [Related]
34. Gp120 V5 Is Targeted by the First Wave of Sequential Neutralizing Antibodies in SHIV
Jia M; Lu H; Kong XP; Cheng-Mayer C; Wu X
Viruses; 2018 May; 10(5):. PubMed ID: 29772652
[TBL] [Abstract][Full Text] [Related]
35. Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains.
Shingai M; Donau OK; Schmidt SD; Gautam R; Plishka RJ; Buckler-White A; Sadjadpour R; Lee WR; LaBranche CC; Montefiori DC; Mascola JR; Nishimura Y; Martin MA
Proc Natl Acad Sci U S A; 2012 Nov; 109(48):19769-74. PubMed ID: 23129652
[TBL] [Abstract][Full Text] [Related]
36. Molecularly cloned SHIV-CN97001: a replication-competent, R5 simian/human immunodeficiency virus containing env of a primary Chinese HIV-1 clade C isolate.
Liu Q; Li Y; Yang G; Dai J; Ruprecht RM; Shao Y
J Med Primatol; 2011 Dec; 40(6):427-36. PubMed ID: 21895680
[TBL] [Abstract][Full Text] [Related]
37. Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis.
Siddappa NB; Hemashettar G; Wong YL; Lakhashe S; Rasmussen RA; Watkins JD; Novembre FJ; Villinger F; Else JG; Montefiori DC; Ruprecht RM
J Med Primatol; 2011 Apr; 40(2):120-8. PubMed ID: 21044092
[TBL] [Abstract][Full Text] [Related]
38. Generation of a replication-competent simian-human immunodeficiency virus, the neutralization sensitivity of which can be enhanced in the presence of a small-molecule CD4 mimic.
Otsuki H; Hishiki T; Miura T; Hashimoto C; Narumi T; Tamamura H; Yoshimura K; Matsushita S; Igarashi T
J Gen Virol; 2013 Dec; 94(Pt 12):2710-2716. PubMed ID: 24026672
[TBL] [Abstract][Full Text] [Related]
39. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques.
Moog C; Dereuddre-Bosquet N; Teillaud JL; Biedma ME; Holl V; Van Ham G; Heyndrickx L; Van Dorsselaer A; Katinger D; Vcelar B; Zolla-Pazner S; Mangeot I; Kelly C; Shattock RJ; Le Grand R
Mucosal Immunol; 2014 Jan; 7(1):46-56. PubMed ID: 23591718
[TBL] [Abstract][Full Text] [Related]
40. A decline in CCL3-5 chemokine gene expression during primary simian-human immunodeficiency virus infection.
Zhao W; Pahar B; Borda JT; Alvarez X; Sestak K
PLoS One; 2007 Aug; 2(8):e726. PubMed ID: 17684570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
